These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36619724)
1. The Effects of Jamali A; Karbalai S; Tefagh G; Jamali R; Ahmadi A Middle East J Dig Dis; 2022 Jan; 14(1):85-95. PubMed ID: 36619724 [No Abstract] [Full Text] [Related]
2. The effect of helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial. Jamali R; Mofid A; Vahedi H; Farzaneh R; Dowlatshahi S Hepat Mon; 2013; 13(12):e14679. PubMed ID: 24358044 [TBL] [Abstract][Full Text] [Related]
3. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Razavizade M; Jamali R; Arj A; Matini SM; Moraveji A; Taherkhani E Hepat Mon; 2013 May; 13(5):e9270. PubMed ID: 23930133 [TBL] [Abstract][Full Text] [Related]
4. Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study. Alavinejad P; Hajiani E; Parsi A; Satari A; Rezaei MJ; Nayebi M; Hormati A; Eslami O; Ahmed MH; Tran QT; Arshadzadeh M; Baghaei S; Mohammadi S; Hashemi SJ; Sedaghat A BMC Gastroenterol; 2022 Dec; 22(1):507. PubMed ID: 36482315 [TBL] [Abstract][Full Text] [Related]
5. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial. Shavakhi A; Minakari M; Firouzian H; Assali R; Hekmatdoost A; Ferns G Int J Prev Med; 2013 May; 4(5):531-7. PubMed ID: 23930163 [TBL] [Abstract][Full Text] [Related]
6. Which Metabolic Index is Appropriate for Predicting Non-alcoholic Steatohepatitis? Jamali R; Ebrahimi M; Faryabi A; Ashraf H Middle East J Dig Dis; 2020 Apr; 12(2):99-105. PubMed ID: 32626562 [TBL] [Abstract][Full Text] [Related]
7. The Effect of Laparoscopic Sleeve Gastrectomy and Gastric Bypass Surgery on Non-Alcoholic Steatohepatitis in Iranian Patients with Obesity. Elyasinia F; Jalali SM; Zarini S; Sadeghian E; Sorush A; Pirouz A Middle East J Dig Dis; 2021 Jul; 13(3):200-207. PubMed ID: 36606220 [TBL] [Abstract][Full Text] [Related]
8. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174 [TBL] [Abstract][Full Text] [Related]
9. Prevalence and associated metabolic factors of fatty liver disease in the elderly. Wang Z; Xu M; Peng J; Jiang L; Hu Z; Wang H; Zhou S; Zhou R; Hultström M; Lai EY Exp Gerontol; 2013 Aug; 48(8):705-9. PubMed ID: 23721951 [TBL] [Abstract][Full Text] [Related]
10. Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial. Shavakhi A; Torki M; Khodadoostan M; Shavakhi S Adv Biomed Res; 2015; 4():212. PubMed ID: 26605241 [TBL] [Abstract][Full Text] [Related]
11. Long-term Effects of the Eradication of Park J; Kim N; Kim WS; Lim SH; Choi Y; Jo HH; Ji E; Yoon H; Shin CM; Park YS; Lee DH Gut Liver; 2023 Jan; 17(1):58-68. PubMed ID: 35770660 [TBL] [Abstract][Full Text] [Related]
12. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. Gen R; Demir M; Ataseven H South Med J; 2010 Mar; 103(3):190-6. PubMed ID: 20134372 [TBL] [Abstract][Full Text] [Related]
13. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis. Abd El-Kader SM; Al-Shreef FM; Al-Jiffri OH Afr Health Sci; 2016 Mar; 16(1):242-9. PubMed ID: 27358638 [TBL] [Abstract][Full Text] [Related]
14. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Sazci A; Akpinar G; Aygun C; Ergul E; Senturk O; Hulagu S Dig Dis Sci; 2008 Dec; 53(12):3218-24. PubMed ID: 18465245 [TBL] [Abstract][Full Text] [Related]
16. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. Sharma BC; Kumar A; Garg V; Reddy RS; Sakhuja P; Sarin SK J Clin Exp Hepatol; 2012 Dec; 2(4):333-7. PubMed ID: 25755455 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423 [TBL] [Abstract][Full Text] [Related]
18. Effect of Vafaeimanesh J; Bagherzadeh M; Mirzaei A; Parham M; Norouzinia M; Vafaee R Gastroenterol Hepatol Bed Bench; 2016 Dec; 9(Suppl1):S36-S41. PubMed ID: 28224026 [TBL] [Abstract][Full Text] [Related]
19. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Sorbi D; Boynton J; Lindor KD Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476 [TBL] [Abstract][Full Text] [Related]
20. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Kuchay MS; Krishan S; Mishra SK; Choudhary NS; Singh MK; Wasir JS; Kaur P; Gill HK; Bano T; Farooqui KJ; Mithal A Diabetologia; 2020 Nov; 63(11):2434-2445. PubMed ID: 32865597 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]